Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma
Microbes & Immunity · 2024
DOI: 10.36922/mi.3445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes & Immunity, 2024. Verfasst von Anupama Balasubramanian und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Talimogene laherparepvec (T-VEC) is currently the only United States Food and Drug Administration-approved intralesional therapy for advanced melanoma. Recent studies have assessed the integration of T-VEC with systemic immunotherapy, though the response remains variable. Therefore, we sought to identify factors associated with the response to T-VEC by conducting a retrospective, single-center analysis involving melanoma patients treated with T-VEC. In the present study, we recorded demographic and clinicopathological data, details of T-VEC treatments, prior and concurrent treatments, and clinical outcomes. The primary endpoint was the in-field overall response rate (ORR: complete + partial). Secondary endpoints included complete in-field response, defined as complete resolution of disease or a negative biopsy; disease failure-free survival (DFFS), defined from the initiation of treatment as the time to progression in patients who did not experience a disease-free interval and time to recurrence in those who did; and overall survival (OS). We used two-sample t-tests for continuous variables and Fisher’s exact test for categorical variables. DFFS and OS were further analyzed using the Kaplan–Meier method and log-rank tests for selected variables. Among the 18 patients who met the inclusion criteria, an in-field response was observed in 14 (78%) patients. Low disease burden (
Zitieren
APA
Balasubramanian, A., Salusti-Simpson, M., Callas, P., O’Neill, C., Rehman, H., Ahmed, S., Sajisevi, M., Anker, C. J., & Cintolo-Gonzalez, J. (2024). Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma. Microbes & Immunity. https://doi.org/10.36922/mi.3445
Vancouver
Balasubramanian A, Salusti-Simpson M, Callas P, O’Neill C, Rehman H, Ahmed S, et al. Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma. Microbes & Immunity. 2024. doi:10.36922/mi.3445
BibTeX
@article{Balasubramanian2024,
author = {Balasubramanian, Anupama and Salusti-Simpson, Michela and Callas, Peter and O’Neill, Conor and Rehman, Hibba and Ahmed, Shahid and Sajisevi, Mirabelle and Anker, Christopher J. and Cintolo-Gonzalez, Jessica},
title = {Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma},
journal = {Microbes & Immunity},
year = {2024},
doi = {10.36922/mi.3445}
}
EUVIMED